SWX:BANBLife Sciences
Bachem (SWX:BANB) Stock Faces Margin Strain As Capex Surges
Bachem Holding walked into this earnings season with a growth-stock label and a rich P/E of 37.6x, yet the share price has drifted down about 3% over the past month to CHF 74.80. Today's H1 numbers put the spotlight on something less glamorous and more important for you as an investor. The peptide and oligonucleotide specialist is pouring money into capacity, with H1 capital expenditure of CHF 148m and EBITDA margin sitting at 25.4%. The key question is whether this heavy build-out and margin...